Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.

Hong Kong Bankers Get Welcome Lift From Convertible Bond FrenzyBanks Funnel Billions More Into Private Credit as Frenzy SpreadsCrescent Capital Pushes into Private Credit With Australia HireGlobal Bonds Slide Once Again as Inflation Curbs Rate-Cut HopesIndian Stocks Tend to Reward Investors Post Polls, History ShowsJPMorgan in Talks to Arrange $1.1 Billion Loan for Logan, KWGIndia’s Near-8% Growth Gives Modi a Boost as Elections EndPanetta Says ECB Cuts Now Avoid ‘Tardy and Hasty’ Action LaterS.

What you should knowFirst 2024 Canada carbon rebates will be deposited today for some CanadiansThe big benefits of adopting a debt-free lifestyleMost young adults think retiring by 65 is outdated: surveyMany Canadians still feeling squeezed even as debt worries ease: insolvency firmHow to avoid OAS clawbacks and other tax traps in retirementSurvey finds nearly half of Canadians feeling 'stuck at work'Solar Company IPO Shows Growing Bets on Philippines Green EnergyUK House Prices...

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 83. in RU

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Amgen's peek at its GLP-1 drug trial results heightens competition in obesity marketCompetition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Источник: YahooFinanceCA - 🏆 47. / 63 Прочитайте больше »